Announcement of providing guarantee for the holding company
Release time:
2020-08-05
Securities Abbreviations: Jianfeng Group Securities Code: 600668 Number: Pro 2019-010
Bond Abbreviations: 13 Peak 02 Bond Code: 122344
Announcement of Zhejiang Jianfeng Group Co., Ltd.
Providing Guarantee for Holding Subsidiaries
The Board of Directors and all directors of the Company guarantee that there are no false records, misleading statements or major omissions in the contents of this announcement, and assumes individual and joint responsibility for the truthfulness, accuracy and completeness of its contents .
Important Content Tips
● Names of Guarantees: Zhejiang Jianfeng Pharmaceutical Co., Ltd., Shanghai Beika Pharmaceutical Technology Co., Ltd. and its wholly-owned subsidiaries, Guizhou Huangpinggu Longmingchuan Cement Co., Ltd., Zhejiang Jianfeng International Trade Co., Ltd.
● To set up a financing guarantee amount: Set up a financing guarantee amount 8.8 .3 billion yuan.
● Is there any counter-guarantee in this guarantee: No
● Cumulative quantity of overdue external guarantee: No
Overview of 1. guarantee
2019 4 26 , zhejiang Jianfeng Group Co., Ltd. held thethnd meeting of the 10th Board of Directors. The company currently has nine directors, eight of whom attended the meeting in person. Director Du Zihong entrusted Director Jiang Xiaomeng to attend the meeting on his behalf and vote , complies with the relevant provisions of the "Company Law" and the company's "Articles of Association", and the resolutions made are legal and valid. The meeting was presided over by Chairman Jiang Xiaomeng. After deliberation and voting, the "Proposal on Providing Guarantees to Holding Subsidiaries" was deliberated and passed with 9 votes in favor, 0 votes against, and 0 abstentions.
The motion needs to be submitted to the shareholders' meeting for consideration.
Basic Information of Guaranteed 2.
1 , Zhejiang Jianfeng Pharmaceutical Co., Ltd. (hereinafter referred to as "Jianfeng Pharmaceutical"), registered capital 19853 Yuan, of which: the company accounts for 99.16% , registered address: on the second floor of No. 87 X02 office quality inspection building, No. 85 58 , Gaofan Section, Baitang Downline, Wucheng District, Jinhua City, Zhejiang Province, is mainly engaged in drug research and development and production (operated with valid licenses); Import raw and auxiliary materials for production and scientific research; Imported mechanical equipment, instruments and spare parts.
, Shanghai Beika Medical Technology Co., Ltd. (hereinafter referred to as "Shanghai Beika"), with a registered capital of 2275.93 yuan, of which: the company accounts for 61.48% , registered address: Building 99 21 , 3802 , Shengang Road, Songjiang District, Shanghai, mainly engaged in: technology development, technical consultation, technical service and technology transfer in the field of medicine and chemistry; wholesale and retail of mechanical equipment, instruments and meters, edible agricultural products (excluding pig products), chemical fertilizers, feed additives, chemical raw materials and products (except dangerous goods); development and sales of pharmaceutical intermediates; import and export of goods and technologies. Shanghai Beika has three wholly-owned subsidiaries: Anhui Xinbeika Chemical Co., Ltd., Anhui Jianfeng Beika Pharmaceutical Co., Ltd., and Anhui Zhongwang Pharmaceutical Co., Ltd. 3
5000 .06 million yuan, the company accounts for 100% , registered address: Gulong Industrial Park, Huangping County, Qiandongnan Miao and Dong Autonomous Prefecture, Guizhou Province, mainly engaged in research and development, production and sales of cement products and process equipment; ordinary Portland cement and commercial concrete, cement products, limestone, artificial sand, gravel, aggregate manufacturing sales. 4
3000 .14 million yuan, of which: the company accounts for 93.33% , Jianfeng Pharmaceutical accounts for 6.67 , registered address: No. 88 , No. 119, changchun West Road, Jindong Economic Development Zone, Zhejiang, mainly engaged in: import and export of goods and technologies permitted by national laws and regulations without pre-approval; road cargo transportation; road transport station (field) operation; food management; sales of pharmaceutical intermediates, pharmaceutical equipment, etc. and online sales; national laws and policies permit Business consulting service activities; carry out international transportation agency business for import and export goods, and general cargo storage services. 3. of the above subsidiaries 2018
financial data (unit: ten thousand yuan)
|
# total 144 liabilities
|
total current liabilities
|
total bank loans
|
net assets
|
Total Operating Income
|
Net Profit Attributed to Owners of Parent Company
|
| Peak Pharmaceutical
144410.77
|
94187.16
|
88383.69
|
4600
|
50223.61
|
148762.44
|
3696.70
|
| Shanghai North Carolina
24853.30
|
10729.36
|
10685.21
|
3700
|
14123.94
|
21469.79
|
-90.77
|
| Peak International Trade
13677.85
|
11564.77
|
11462.27
|
|
2113.08 |
14443.11
|
567.82
|
| Mingchuan, Guizhou
6955.58
|
7633.27
|
7633.27
|
|
-677.70 |
0
|
-240.56
|
|
, the guarantee provided by the holding subsidiary to borrow money from financial institutions, set the following limits:
Limit (RMB 10,000)
|
| Zhejiang Jianfeng Pharmaceutical Co., Ltd.
30000
|
| Shanghai Beika Pharmaceutical technology Co., Ltd. and its wholly-owned subsidiary
20000
|
| Guizhou Huangpinggu Longmingchuan Cement Co., Ltd.
30000
|
| Zhejiang Jianfeng International Trade Co., Ltd.
8000
|
|
More information
The company fully deploys 2018 work
On January 27, the group company held a business analysis meeting to review and summarize the work in 2017, arrange and deploy the work for the new year, and put forward work requirements. At the meeting, various professional companies and directly affiliated enterprises reported on the overall work situation in 2017, focusing on analyzing the existing problems and deficiencies, and proposing corresponding solutions and work plans for 2018. Xiang Chongping, deputy general manager of the group company, systematically combed the current human resources efficiency and human resources development of the company. Chen Tianci, chairman of the board of supervisors, made a report and analysis on the "three reductions and three improvements" and the safety and environmental protection work in 2017. Lan Xiaolong, head of finance, analyzed the risks and challenges currently faced by the company according to the operating data and financial situation of its subordinate enterprises. The functional departments and offices of the headquarters also made a brief report on their annual work. Yu Jianhong, general manager of the group company, made a comprehensive review of the company's operation in 2017, compared and analyzed the main economic indicators of various industrial sectors, and pointed out that looking for new investment and development projects around strategic objectives, promoting the optimization of organizational structure and post setting, significantly improving the level of information management, improving the ability of fund management and tax planning, achieving certain results in scientific and technological innovation and technological transformation, and strengthening marketing management and market expansion, safety and environmental protection work is basically up to standard, training and talent development have achieved new results and other work highlights; at the same time, it summarizes and reflects on the shortcomings in strategic decision-making, management innovation, performance appraisal, market operation, and talent team building. After analyzing the current macroeconomic situation and the future trends of various related industries, Yu Jianhong informed
2020
07-31
Peak Pharmaceutical Invests in Shanghai North Carolina to Build API R & D and Production Base
News from our newspaper On January 19, the group company held the second meeting of the tenth board of directors and reviewed and approved the "Proposal on Foreign Investment of Subsidiary Jianfeng Pharmaceutical." On the same day, Jianfeng Pharmaceutical signed an agreement to invest in Shanghai North Carolina Pharmaceutical Technology Co., Ltd. (hereinafter referred to as "Shanghai North Carolina") by acquiring shares and increasing capital. Shanghai Beika is a high-tech enterprise in Shanghai. It has an academician expert workstation and a number of Shanghai high-tech achievements transformation projects. It has won the title of "second prize for scientific and technological progress" in Songjiang District, Shanghai, "patent pilot enterprise" and "enterprise technology center" in Songjiang District, Shanghai. The company has strong research and development capabilities and has obtained 14 patents. At present, its main business is to provide products and customized services for domestic and foreign pharmaceutical companies. The products mainly include Tinib, alkaloids, carbohydrates and other anti-tumor drug intermediates. The customized services are mainly CDMO (contract development and manufacturing) of new drugs and intermediates. Shanghai North Carolina has two wholly-owned subsidiaries, Anhui Changtai Chemical Co., Ltd. (hereinafter referred to as "Changtai Chemical") and Anhui North Carolina Pharmaceutical Co., Ltd. (hereinafter referred to as "Anhui North Carolina"). Changtai Chemical is a pesticide manufacturer designated by the Ministry of Industry and Information Technology. It was established in July 2007. It now has three chemical synthesis workshops and a pesticide preparation compounding workshop, with 10 product approvals and 13 patents. Anhui North Carolina was established in December 2016. Its business scope includes the customization, production and sales of chemical raw materials and pharmaceutical intermediates, and the wholesale and retail of chemical raw materials and products (except hazardous chemicals
2020
07-30
Peak Pharmaceutical Invests in Shanghai North Carolina to Build API R & D and Production Base
News from our newspaper On January 19, the group company held the second meeting of the tenth board of directors and reviewed and approved the "Proposal on Foreign Investment of Subsidiary Jianfeng Pharmaceutical." On the same day, Jianfeng Pharmaceutical signed an agreement to invest in Shanghai North Carolina Pharmaceutical Technology Co., Ltd. (hereinafter referred to as "Shanghai North Carolina") by acquiring shares and increasing capital. Shanghai Beika is a high-tech enterprise in Shanghai. It has an academician expert workstation and a number of Shanghai high-tech achievements transformation projects. It has won the title of "second prize for scientific and technological progress" in Songjiang District, Shanghai, "patent pilot enterprise" and "enterprise technology center" in Songjiang District, Shanghai. The company has strong research and development capabilities and has obtained 14 patents. At present, its main business is to provide products and customized services for domestic and foreign pharmaceutical companies. The products mainly include Tinib, alkaloids, carbohydrates and other anti-tumor drug intermediates. The customized services are mainly CDMO (contract development and manufacturing) of new drugs and intermediates. Shanghai North Carolina has two wholly-owned subsidiaries, Anhui Changtai Chemical Co., Ltd. (hereinafter referred to as "Changtai Chemical") and Anhui North Carolina Pharmaceutical Co., Ltd. (hereinafter referred to as "Anhui North Carolina"). Changtai Chemical is a pesticide manufacturer designated by the Ministry of Industry and Information Technology. It was established in July 2007. It now has three chemical synthesis workshops and a pesticide preparation compounding workshop, with 10 product approvals and 13 patents. Anhui North Carolina was established in December 2016. Its business scope includes the customization, production and sales of chemical raw materials and pharmaceutical intermediates, and the wholesale and retail of chemical raw materials and products (except hazardous chemicals
2020
07-31
Jianfeng Pharmaceutical was rated as a provincial trademark brand demonstration enterprise
On December 28, 2017, Zhejiang Administration for Industry and Commerce announced the list of trademark brand demonstration counties (cities, districts), demonstration towns (streets) and demonstration enterprises in Zhejiang Province in 2017. Jianfeng Pharmaceutical Company was identified as a trademark brand demonstration enterprise, and it was also the only enterprise in Jinhua City to enter the list. Peak Pharmaceutical was established in 1998 and obtained the first registered trademark in 1999. Since then, Jianfeng Pharmaceutical has been actively carrying out brand building in accordance with the requirements of the Trademark Law and other laws and regulations, and has set up an intellectual property department to carry out trademark management, rights protection and other activities; it has established a sound trademark management system, strictly in accordance with the provisions of the Trademark Law to supervise and manage the use of trademarks inside and outside the enterprise, and safeguard the legitimate rights and interests of the enterprise. Establish strategic cooperation with professional institutions, for trademark applications, renewals and other work. In recent years, Jianfeng Pharmaceutical has also explored trademark investment, creating value through intangible assets such as trademarks and brands, promoting efficiency improvement, and further expanding corporate influence; at the same time, it has continuously increased investment in new product research and development and technological transformation, and actively Declare various patents to provide strong support for brand building with technological innovation. According to incomplete statistics, Jianfeng Pharmaceutical and its subsidiaries currently have more than 120 valid trademarks, including 1 well-known trademark in China, 2 well-known trademarks in Zhejiang Province, 5 well-known trademarks in Jinhua City, and 2 overseas registered trademarks; Obtained more than 40 domestic and international patents. Trademark is an important part of intellectual property rights, in the knowledge economy, brand effect is increasingly becoming the leading force of economic development.
2020
07-31
Peak Pharmaceutical Invests in Shanghai North Carolina to Build API R & D and Production Base
News from our newspaper On January 19, the group company held the second meeting of the tenth board of directors and reviewed and approved the "Proposal on Foreign Investment of Subsidiary Jianfeng Pharmaceutical." On the same day, Jianfeng Pharmaceutical signed an agreement to invest in Shanghai North Carolina Pharmaceutical Technology Co., Ltd. (hereinafter referred to as "Shanghai North Carolina") by acquiring shares and increasing capital. Shanghai Beika is a high-tech enterprise in Shanghai. It has an academician expert workstation and a number of Shanghai high-tech achievements transformation projects. It has won the title of "second prize for scientific and technological progress" in Songjiang District, Shanghai, "patent pilot enterprise" and "enterprise technology center" in Songjiang District, Shanghai. The company has strong research and development capabilities and has obtained 14 patents. At present, its main business is to provide products and customized services for domestic and foreign pharmaceutical companies. The products mainly include Tinib, alkaloids, carbohydrates and other anti-tumor drug intermediates. The customized services are mainly CDMO (contract development and manufacturing) of new drugs and intermediates. Shanghai North Carolina has two wholly-owned subsidiaries, Anhui Changtai Chemical Co., Ltd. (hereinafter referred to as "Changtai Chemical") and Anhui North Carolina Pharmaceutical Co., Ltd. (hereinafter referred to as "Anhui North Carolina"). Changtai Chemical is a pesticide manufacturer designated by the Ministry of Industry and Information Technology. It was established in July 2007. It now has three chemical synthesis workshops and a pesticide preparation compounding workshop, with 10 product approvals and 13 patents. Anhui North Carolina was established in December 2016. Its business scope includes the customization, production and sales of chemical raw materials and pharmaceutical intermediates, and the wholesale and retail of chemical raw materials and products (except hazardous chemicals
2020
07-31
The company was rated as an advanced unit of the city's focus on talent and love talent.
News from our newspaper On December 11, the Talent Work Leading Group of the Jinhua Municipal Committee of the Communist Party of China commended the advanced units of Jinhua City that value talents and love talents. 36 units including Jianfeng Group won this honor. The selection of advanced units that value talents and love talents is a measure taken by the Jinhua Municipal Party Committee to further create a good atmosphere of focusing on talents and loving talents, fully respect and make good use of the first resource of talents, serve innovation to drive development, and implement the development strategy of strengthening the province with talents and innovation. The enterprises and institutions that have won this honorary title have always regarded talents as the fundamental driving force for development for a long time, regarded the investment of talents as the most effective investment, and integrated the love of talents into the unit culture. Remarkable achievements have been made in gathering talents, achieving talents, transforming and upgrading, and accelerating development. The Jinhua Municipal Party Committee requires the majority of employers to learn from advanced units, vigorously promote the trend of focusing on talents and loving talents, remove the obstacles to the talent development system and mechanism, and in accordance with the requirements of "walking in the forefront and jointly building Jinhua", in order to promote the construction of a modern metropolitan area and accelerate the construction of the province An important growth pole for high-quality development provides talent support and intellectual guarantee. (this newspaper reporter)
2020
07-31